Genetic heterogeneity contributes to clinical outcome and progression of most tumors, but
little is known about allelic diversity for epigenetic compartments, and almost no data exist …

Purpose To evaluate the prognostic significance of the international European LeukemiaNet
(ELN) guidelines for reporting genetic alterations in acute myeloid leukemia (AML). Patients …

The relationships between normal and leukemic stem/progenitor cells are unclear. We show
that in∼ 80% of primary human CD34+ acute myeloid leukemia (AML), two expanded …

Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of
cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes …

Patients with secondary acute myeloid leukemia (AML) often escape inclusion in clinical
trials and thus, population‐based studies are crucial for its accurate characterization. In this …

The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-
versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated …

In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high
mortality among patients. However, the mechanisms that render leukemic cells drug …

Abstract The revised 2022 European LeukemiaNet (ELN) AML risk stratification system
requires validation in large, homogeneously treated cohorts. We studied 1118 newly …

Recurring deletions of chromosome 7 and 7q [− 7/del (7q)] occur in myelodysplastic
syndromes and acute myeloid leukemia (AML) and are associated with poor prognosis …

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation
(HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete …